Aarti Pharmalabs FY26 Performance and Growth Strategy

Revenue at Rs 1,819.44 crore; PAT at Rs 174.71 crore.

Reader Takeaway: Heavy capex in Xanthine and Atali facilities aims for long-term growth despite current margin pressure.

What just happened

Aarti Pharmalabs has announced its financial results for FY 2025-26, highlighting a year of transition. The company recorded an annual revenue of Rs 1,819.44 crore and a profit after tax of Rs 174.71 crore. Shareholders will receive a final dividend of Rs 2.00 per equity share, which follows an earlier interim payout, bringing the total dividend for the year to Rs 3.50 per share. Financial results for the year are not strictly comparable to FY 2024-25 due to the change in accounting treatment for Ganesh Polychem Limited.

Why this matters

The company underwent a year of "purposeful investment," deploying Rs 400 crore into capacity building. This capital expenditure is designed to solidify the company's position in complex chemistries, particularly Xanthine derivatives, where it plans to grow its global market share from the current 15-20% to 20-25%. While profitability metrics like EBITDA and PAT were impacted by initial commissioning costs and raw material inflation, management remains confident in its medium-term guidance of 15-18% revenue and EBITDA CAGR.

Business and Operational Performance

The Xanthine derivatives segment emerged as a primary contributor with Rs 792 crore in revenue. The company is actively expanding this facility at Tarapur to 9,000 MTPA, scheduled for commissioning in June 2026. Conversely, the API and Intermediates segment, contributing Rs 600 crore, faced headwinds from pricing corrections and customer inventory adjustments. The CDMO and CMO business showed strong momentum, growing 32% to reach Rs 276 crore, supported by 54 active projects with 21 customers.

Risks to watch

Investors should monitor the impact of raw material price volatility and potential pricing pressures in the API sector, which weighed on margins throughout the year. The success of the current strategy hinges on the efficient utilization of the expanded Atali platform and the timely ramp-up of the Tarapur facility.

What to track next

The market will look for improvements in capacity utilization levels across the newly commissioned facilities. The net debt-to-equity ratio, currently at a healthy 0.32x, provides the company with the financial flexibility to execute these ongoing expansion plans.